Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.48 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.48 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.48 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.48 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653212 | 0.85 | STAT3 (0.53) | STAT3TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL653340 | 0.81 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL651589 | 0.78 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10019302 | 0.74 | KDM4E (0.47) | KMT2APOLBMEN1ALDH1A1GAA | |
| SCHEMBL12359757 | 0.74 | PPARG (0.55) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL652355 | 0.73 | TUBB4A (0.73) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL931908 | 0.73 | HTR6 (0.62) | HTR6KMT2APOLBL3MBTL1MEN1 | |
| SCHEMBL949160 | 0.73 | HTR6 (0.76) | HTR6KMT2APOLBL3MBTL1MEN1 | |
| SCHEMBL650161 | 0.73 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3965144 | 0.72 | HTR6 (0.70) | HTR6KMT2APOLBL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550257-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | Lead Discovery Center GmbH (DE) | 2013-01-30 | — | — | EP | disclosed |
| US-8119683-B2 | Aryl substituted sulfonamide compounds and their use as anticancer agents | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-02-21 | — | — | US | disclosed |
| US-8119683-B2 | Aryl substituted sulfonamide compounds and their use as anticancer agents | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-02-21 | — | — | US | disclosed |
| WO-2011116951-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2011-09-29 | — | — | WO | disclosed |
| US-20110039880-A1 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-02-17 | — | — | US | disclosed |
| US-20110039880-A1 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-02-17 | — | — | US | disclosed |
| WO-2011019634-A2 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011019634-A2 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-02-17 | — | — | WO | disclosed |
| WO-2004113301-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039880-A1 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | ARSA, SULT1E1, STS | STAT3 1959/4885TUBB4A 724/4885TUBB 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.